Cargando…

Safety and Immunogenicity of Therapeutic DNA Vaccination in Individuals Treated with Antiretroviral Therapy during Acute/Early HIV-1 Infection

BACKGROUND: An effective therapeutic vaccine that could augment immune control of HIV-1 replication may abrogate or delay the need for antiretroviral therapy. AIDS Clinical Trials Group (ACTG) A5187 was a phase I/II, randomized, placebo-controlled, double-blinded trial to evaluate the safety and imm...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rosenberg, Eric S., Graham, Barney S., Chan, Ellen S., Bosch, Ronald J., Stocker, Vicki, Maenza, Janine, Markowitz, Martin, Little, Susan, Sax, Paul E., Collier, Ann C., Nabel, Gary, Saindon, Suzanne, Flynn, Theresa, Kuritzkes, Daniel, Barouch, Dan H.
Formato:	Texto
Lenguaje:	English
Publicado:	Public Library of Science 2010
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2866663/ https://www.ncbi.nlm.nih.gov/pubmed/20479938 http://dx.doi.org/10.1371/journal.pone.0010555

Ejemplares similares

Cells producing residual viremia during antiretroviral treatment appear to contribute to rebound viremia following interruption of treatment
por: Aamer, Hadega A., et al.
Publicado: (2020)

A Pilot Study of Raltegravir Plus Combination Antiretroviral Therapy in Early Human Immunodeficiency Virus Infection: Challenges and Lessons Learned
por: Collier, Ann C., et al.
Publicado: (2016)

Impact of HLA Class I Alleles on Timing of HIV Rebound After Antiretroviral Treatment Interruption
por: Park, You Jeong, et al.
Publicado: (2017)

Evolution of resistance in paediatric patients with failure on antiretroviral therapy
por: Orrell, C, et al.
Publicado: (2012)

Improving on effective antiretroviral therapy: how good will a cure have to be?
por: Freedberg, Kenneth A, et al.
Publicado: (2017)

The Effect of Modern Antiretroviral Therapy on Complication Rates After Total Hip Arthroplasty
por: Sax, Oliver C., et al.
Publicado: (2021)

Priming Immunization with DNA Augments Immunogenicity of Recombinant Adenoviral Vectors for Both HIV-1 Specific Antibody and T-Cell Responses
por: Koup, Richard A., et al.
Publicado: (2010)

Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule
por: Sullivan, Nancy J., et al.
Publicado: (2009)

Transforming epitope-specific gp120 monomer-based probes into immunogens with N-linked glycan masking
por: Chuang, G, et al.
Publicado: (2012)

Prevalence and Impact of Minority Variant Drug Resistance Mutations in Primary HIV-1 Infection
por: Stekler, Joanne D., et al.
Publicado: (2011)

Safety and Immunogenicity of DNA Vaccines Encoding Ebolavirus and Marburgvirus Wild-Type Glycoproteins in a Phase I Clinical Trial
por: Sarwar, Uzma N., et al.
Publicado: (2015)

108. Selective Decay of Intact HIV-1 Proviral DNA on Antiretroviral Therapy
por: Gandhi, Rajesh, et al.
Publicado: (2020)

Full-length HIV-1 immunogens induce greater T lymphocyte responses to conserved epitopes than conserved-region-only HIV-1 immunogens in monkeys
por: Stephenson, KE, et al.
Publicado: (2012)

DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials
por: Ledgerwood, Julie E, et al.
Publicado: (2011)

Immunogenicity and Cross-Reactivity of Rhesus Adenoviral Vectors
por: Iampietro, M. Justin, et al.
Publicado: (2018)

Adherence to antiretroviral treatment regimens and correlation with risk of hospitalization among commercially insured HIV patients in the US
por: Sax, PE, et al.
Publicado: (2010)

Interactions of HIV and Antiretroviral Therapy With Neutrophils and Platelets
por: Madzime, Morris, et al.
Publicado: (2021)

Levels of HIV-1 persistence on antiretroviral therapy are not associated with markers of inflammation or activation
por: Gandhi, Rajesh T., et al.
Publicado: (2017)

Real-Time Predictions of Reservoir Size and Rebound Time during Antiretroviral Therapy Interruption Trials for HIV
por: Hill, Alison L., et al.
Publicado: (2016)

Emergent Resistance to Dolutegravir Among INSTI-Naïve Patients on First-line or Second-line Antiretroviral Therapy: A Review of Published Cases
por: Cevik, Muge, et al.
Publicado: (2020)

Safety and Immunogenicity of a rAd35-EnvA Prototype HIV-1 Vaccine in Combination with rAd5-EnvA in Healthy Adults (VRC 012)
por: Crank, Michelle C., et al.
Publicado: (2016)

Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters
por: Collier, Ai-ris Y., et al.
Publicado: (2023)

Immunogenicity of the BA.5 Bivalent mRNA Vaccine Boosters
por: Collier, Ai-ris Y., et al.
Publicado: (2022)

Adherence to Antiretroviral Treatment and Correlation with Risk of Hospitalization among Commercially Insured HIV Patients in the United States
por: Sax, Paul E., et al.
Publicado: (2012)

Coronavirus Disease 2019 Messenger RNA Vaccine Immunogenicity in Immunosuppressed Individuals
por: Collier, Ai-ris Y, et al.
Publicado: (2021)

Correction: Real-Time Predictions of Reservoir Size and Rebound Time during Antiretroviral Therapy Interruption Trials for HIV
por: Hill, Alison L., et al.
Publicado: (2017)

Antibody Responses After Analytic Treatment Interruption in Human Immunodeficiency Virus-1-Infected Individuals on Early Initiated Antiretroviral Therapy
por: Stephenson, Kathryn E., et al.
Publicado: (2016)

X-linked Agammaglobulinemia Presenting with Multiviral Pneumonia
por: Arroyo-Martinez, Yadis M, et al.
Publicado: (2020)

1242. Safety and Immunogenicity of Novel 24-Valent Pneumococcal Vaccine in Healthy Adults
por: Chichili, Gurunadh, et al.
Publicado: (2020)

Author Correction: Next-generation influenza vaccines: opportunities and challenges
por: Wei, Chih-Jen, et al.
Publicado: (2020)

Next-generation influenza vaccines: opportunities and challenges
por: Wei, Chih-Jen, et al.
Publicado: (2020)

Safety and Efficacy of Starting Antiretroviral Therapy in the First Week of Life
por: Maswabi, Kenneth, et al.
Publicado: (2020)

Altered Monocyte Phenotype in HIV-1 Infection Tends to Normalize with Integrase-Inhibitor-Based Antiretroviral Therapy
por: McCausland, Marie R., et al.
Publicado: (2015)

Editorial: Immunogenicity of Proteins Used as Therapeutics
por: Sauna, Zuben E., et al.
Publicado: (2020)

Rationing Antiretroviral Therapy for HIV/AIDS in Africa: Choices and Consequences
por: Rosen, Sydney, et al.
Publicado: (2005)

Peripheral blood biomarkers predict viral rebound following antiretroviral therapy discontinuation in SIV-infected, early ART-treated rhesus macaques
por: Aid, Malika, et al.
Publicado: (2023)

Hyperglycosylated resurfaced stabilized GP120 core as an immunogen elicits antibodies targeted at the CD4-binding site
por: Dai, K, et al.
Publicado: (2012)

Immunogenicity of allogeneic mesenchymal stem cells
por: Schu, Sabine, et al.
Publicado: (2012)

892. Determination of the Unavailability of Alternative Antiretroviral Formulations
por: Murray, Milena M, et al.
Publicado: (2021)

P14-10. Comparable immunogenicity of VRC DNA and rAd5 HIV-1 vaccines delivered by intramuscular, subcutaneous and intradermal routes in healthy adults (VRC 011)
por: Ledgerwood, JE, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_7h3aut0c8uhfof5etrovasqelt